Recent Finacing
Recent Raise
Emendo Biotherapeutics develops OMNI, an allele-specific gene-editing platform that combines synthetic biology, engineered CRISPR nucleases and protein engineering to edit dominant genetic diseases like ELANE-associated SCN.
